Lactobacillus Fermentum Treats Fructose-Related Diseases (EP3768286A1)
Summary
EPO published patent application EP3768286A1 on April 8, 2026, covering Lactobacillus fermentum compositions for treating fructose-related diseases. The patent names AixSwiss B.V. as applicant and lists PAULE, Jörg and OESTER, Fabio as inventors. The designation covers 31 European states including all major EU markets.
What changed
EPO granted patent EP3768286A1 for Lactobacillus fermentum compositions effective for treating fructose-related diseases. The patent application was filed by AixSwiss B.V. with inventors PAULE and OESTER, covering compositions containing the probiotic strain in pharmaceutical formulations. Designated states include all EU member states plus Switzerland, Norway, and other European countries.
For competitors in the probiotic or metabolic disease treatment space, this patent establishes intellectual property rights that may restrict freedom to operate with similar compositions for fructose-related disease indications in European markets. Manufacturers should consider design-around options or licensing opportunities.
What to do next
- Monitor for patent maintenance fee deadlines
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LACTOBACILLUS FERMENTUM FOR TREATING FRUCTOSE-RELATED DISEASES
Publication EP3768286A1 Kind: A1 Apr 08, 2026
Applicants
AixSwiss B.V.
Inventors
PAULE, Jörg, OESTER, Fabio
IPC Classifications
A61K 35/747 20150101AFI20190927BHEP A61P 1/00 20060101ALI20190927BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.